Home > Oncology > Pembrolizumab plus bevacizumab and oral cyclophosphamide beneficial in recurrent ovarian cancer

Pembrolizumab plus bevacizumab and oral cyclophosphamide beneficial in recurrent ovarian cancer

Journal
JAMA Oncology
Reuters Health - 02/12/2020 - In patients with recurrent ovarian cancer, the combination of pembrolizumab plus bevacizumab and oral cyclophosphamide demonstrated clinical benefit and was well-tolerated in a phase 2 nonrandomized trial. "We used pembrolizumab to activate T cells; bevacizumab to help T cells to enter tumor tissue; and oral cyclophosphamide to deplete the bad immunosuppressive T-reg immune cells," Dr. Emese Zsiros of Roswell Park Comprehensive Cancer Center in Buffalo in New York told Reuters Health by email. "Overall, this triple therapy regimen was very well tolerated in these women, with three responding completely, 16 responding partially, 22 patients with stable disease, and a disease control rate of 95%." "Currently, bevacizumab and oral cyclophosphamide is an NCCN-approved regimen and commercially available to treat ovarian cancer patients," he noted. "However, with the dual combination, the response rates are not as high and durable." "I...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on